Leon J De Windt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6124904/publications.pdf

Version: 2024-02-01

148 papers	12,158 citations	19608 61 h-index	25716 108 g-index
153 all docs	153 docs citations	153 times ranked	15258 citing authors

#	ARTICLE	IF	CITATIONS
1	The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO Journal, 2000, 19, 6341-6350.	3.5	690
2	MiR423-5p As a Circulating Biomarker for Heart Failure. Circulation Research, 2010, 106, 1035-1039.	2.0	595
3	Long noncoding RNA <i>Chast</i> promotes cardiac remodeling. Science Translational Medicine, 2016, 8, 326ra22.	5.8	321
4	The Transcription Factors GATA4 and GATA6 Regulate Cardiomyocyte Hypertrophy in Vitro and in Vivo. Journal of Biological Chemistry, 2001, 276, 30245-30253.	1.6	310
5	Myocyte apoptosis in heart failure. Cardiovascular Research, 2005, 67, 21-29.	1.8	309
6	Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1283-H1299.	1.5	307
7	MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nature Cell Biology, 2010, 12, 1220-1227.	4.6	289
8	Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1196-1201.	3.3	282
9	Conditional <i>Dicer</i> Gene Deletion in the Postnatal Myocardium Provokes Spontaneous Cardiac Remodeling. Circulation, 2008, 118, 1567-1576.	1.6	282
10	A Calcineurin-NFATc3-Dependent Pathway Regulates Skeletal Muscle Differentiation and Slow Myosin Heavy-Chain Expression. Molecular and Cellular Biology, 2000, 20, 6600-6611.	1.1	271
11	Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2014, 63, 920-927.	1.2	270
12	Targeted Disruption of NFATc3 , but Not NFATc4 , Reveals an Intrinsic Defect in Calcineurin-Mediated Cardiac Hypertrophic Growth. Molecular and Cellular Biology, 2002, 22, 7603-7613.	1.1	241
13	<scp>MicroRNAs</scp> in heart failure: from biomarker to target for therapy. European Journal of Heart Failure, 2016, 18, 457-468.	2.9	235
14	Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure. Circulation, 2013, 128, 1420-1432.	1.6	225
15	Regulation of fetal gene expression in heart failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2414-2424.	1.8	223
16	Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart. Journal of Biological Chemistry, 2000, 275, 13571-13579.	1.6	205
17	Calcineurin-Mediated Hypertrophy Protects Cardiomyocytes From Apoptosis In Vitro and In Vivo. Circulation Research, 2000, 86, 255-263.	2.0	203
18	MEK1-ERK2 Signaling Pathway Protects Myocardium From Ischemic Injury In Vivo. Circulation, 2004, 109, 1938-1941.	1.6	203

#	ARTICLE	IF	CITATIONS
19	Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3322-3327.	3.3	196
20	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	1.0	195
21	The Hypoxia-Inducible MicroRNA Cluster miR-199aâ^¼214 Targets Myocardial PPARÎ´ and Impairs Mitochondrial Fatty Acid Oxidation. Cell Metabolism, 2013, 18, 341-354.	7.2	193
22	PKCÎ± regulates the hypertrophic growth of cardiomyocytes through extracellular signalâ€"regulated kinase1/2 (ERK1/2). Journal of Cell Biology, 2002, 156, 905-919.	2.3	185
23	Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9607-9612.	3.3	160
24	Temporally Controlled Onset of Dilated Cardiomyopathy Through Disruption of the SRF Gene in Adult Heart. Circulation, 2005, 112, 2930-2939.	1.6	151
25	The Dual-Specificity Phosphatase MKP-1 Limits the Cardiac Hypertrophic Response In Vitro and In Vivo. Circulation Research, 2001, 88, 88-96.	2.0	149
26	Calcineurin Expression, Activation, and Function in Cardiac Pressure-Overload Hypertrophy. Circulation, 2000, 101, 2431-2437.	1.6	143
27	Estrogenic hormone action in the heart: regulatory network and function. Cardiovascular Research, 2002, 53, 709-719.	1.8	137
28	Myocyte hypertrophy and apoptosis: a balancing act. Cardiovascular Research, 2004, 63, 487-499.	1.8	137
29	NFATc2 Is a Necessary Mediator of Calcineurin-dependent Cardiac Hypertrophy and Heart Failure. Journal of Biological Chemistry, 2008, 283, 22295-22303.	1.6	136
30	MicroRNAs in control of cardiac hypertrophy. Cardiovascular Research, 2012, 93, 563-572.	1.8	135
31	Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. European Heart Journal, 2003, 24, 883-896.	1.0	131
32	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overloadâ€"Induced Heart Failure. Hypertension, 2018, 71, 280-288.	1.3	128
33	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nature Cell Biology, 2013, 15, 1282-1293.	4.6	126
34	Î²-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19762-19767.	3.3	121
35	MEF2 Activates a Genetic Program Promoting Chamber Dilation and Contractile Dysfunction in Calcineurin-Induced Heart Failure. Circulation, 2006, 114, 298-308.	1.6	120
36	Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7327-7332.	3.3	118

#	ARTICLE	IF	CITATIONS
37	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	2.9	118
38	Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy. Journal of Biological Chemistry, 2002, 277, 48617-48626.	1.6	114
39	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 725-736.	1.8	114
40	EUK-8, a Superoxide Dismutase and Catalase Mimetic, Reduces Cardiac Oxidative Stress and Ameliorates Pressure Overload-Induced Heart Failure in the Harlequin Mouse Mutant. Journal of the American College of Cardiology, 2006, 48, 824-832.	1.2	110
41	MCIP1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction. Circulation Research, 2004, 94, e18-26.	2.0	104
42	Downregulation of Apoptosis-Inducing Factor in Harlequin Mutant Mice Sensitizes the Myocardium to Oxidative Stressâ€“Related Cell Death and Pressure Overloadâ€“Induced Decompensation. Circulation Research, 2005, 96, e92-e101.	2.0	104
43	17Î²-Estradiol Antagonizes Cardiomyocyte Hypertrophy by Autocrine/Paracrine Stimulation of a Guanylyl Cyclase A Receptor-Cyclic Guanosine Monophosphate-Dependent Protein Kinase Pathway. Circulation, 2004, 109, 269-276.	1.6	99
44	Enhanced Activity of the Myocardial Na + /H + Exchanger NHE-1 Contributes to Cardiac Remodeling in Atrial Natriuretic Peptide Receptorâ€“Deficient Mice. Circulation, 2005, 112, 2307-2317.	1.6	99
45	Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 1557-1571.	1.2	99
46	Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovascular Research, 2002, 53, 806-821.	1.8	96
47	Activation of PPARÎ´ inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovascular Research, 2007, 75, 519-529.	1.8	94
48	Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4377-4382.	3.3	90
49	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	2.9	90
50	Calcineurin Is Necessary for the Maintenance but Not Embryonic Development of Slow Muscle Fibers. Molecular and Cellular Biology, 2005, 25, 6629-6638.	1.1	88
51	A Deep Sequencing Approach to Uncover the miRNOME in the Human Heart. PLoS ONE, 2013, 8, e57800.	1.1	88
52	Circulating miRNAs: Reflecting or Affecting Cardiovascular Disease?. Current Hypertension Reports, 2012, 14, 498-509.	1.5	83
53	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	2.9	81
54	Translational Perspective on Epigenetics inÂCardiovascular Disease. Journal of the American College of Cardiology, 2017, 70, 590-606.	1.2	76

#	ARTICLE	IF	CITATIONS
55	Preâ€eclampsia: an important risk factor for asymptomatic heart failure. Ultrasound in Obstetrics and Gynecology, 2017, 49, 143-149.	0.9	74
56	NF-ÂB activation is required for adaptive cardiac hypertrophy. Cardiovascular Research, 2009, 84, 416-424.	1.8	73
57	Cooperative Synergy between NFAT and MyoD Regulates Myogenin Expression and Myogenesis. Journal of Biological Chemistry, 2008, 283, 29004-29010.	1.6	72
58	HypoxamiRs: regulators of cardiac hypoxia and energy metabolism. Trends in Endocrinology and Metabolism, 2015, 26, 502-508.	3.1	72
59	Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load. European Journal of Heart Failure, 2011, 13, 1275-1282.	2.9	70
60	Reversal of Cardiac Hypertrophy in Transgenic Disease Models by Calcineurin Inhibition. Journal of Molecular and Cellular Cardiology, 2000, 32, 697-709.	0.9	69
61	Dominant-Negative Control of cAMP-Dependent I _{Ks} Upregulation in Human Long-QT Syndrome Type 1. Circulation Research, 2012, 110, 211-219.	2.0	61
62	Cardiac <scp>LXR</scp> Î± protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Molecular Medicine, 2015, 7, 1229-1243.	3.3	58
63	Accelerated Development of Pressure Overloadâ€“Induced Cardiac Hypertrophy and Dysfunction in an RyR2-R176Q Knockin Mouse Model. Hypertension, 2010, 55, 932-938.	1.3	57
64	Small changes can make a big difference â€” MicroRNA regulation of cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 2012, 52, 74-82.	0.9	55
65	Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor. Circulation Research, 2010, 106, 155-165.	2.0	54
66	Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion. Journal of the American College of Cardiology, 2004, 44, 1113-1123.	1.2	51
67	Local Atrial Natriuretic Peptide Signaling Prevents Hypertensive Cardiac Hypertrophy in Endothelial Nitric-oxide Synthase-deficient Mice. Journal of Biological Chemistry, 2005, 280, 21594-21599.	1.6	49
68	An SRF/miR-1 axis regulates NCX1 and Annexin A5 protein levels in the normal and failing heart. Cardiovascular Research, 2013, 98, 372-380.	1.8	49
69	Left ventricular pressure?volume measurements in mice: Comparison of closed?chest versus open?chest approach. Basic Research in Cardiology, 2004, 99, 351-9.	2.5	48
70	Regulation of Cardiac Gene Expression by KLF15, a Repressor of Myocardin Activity. Journal of Biological Chemistry, 2010, 285, 27449-27456.	1.6	48
71	Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Frontiers in Genetics, 2013, 4, 214.	1.1	48
72	Modeling Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D Cultures. International Journal of Molecular Sciences, 2020, 21, 3404.	1.8	46

#	ARTICLE	IF	CITATIONS
73	Wnt/Î²-catenin pathway in arrhythmogenic cardiomyopathy. Oncotarget, 2017, 8, 60640-60655.	0.8	46
74	Reparative myocardial mechanisms in adult C57BL/6 and MRL mice following injury. Physiological Genomics, 2007, 30, 44-52.	1.0	45
75	MicroRNAs as Biomarkers for Myocardial Infarction. Current Atherosclerosis Reports, 2012, 14, 193-200.	2.0	43
76	Non-coding RNA in control of gene regulatory programs in cardiac development and disease. Journal of Molecular and Cellular Cardiology, 2015, 89, 51-58.	0.9	43
77	Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice. PLoS ONE, 2016, 11, e0150236.	1.1	42
78	Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure. Molecular Therapy, 2019, 27, 584-599.	3.7	41
79	Left Ventricular Hypertrophy: A Shift in Paradigm. Current Medicinal Chemistry, 2007, 14, 157-171.	1.2	40
80	A novel murine model for arrhythmogenic cardiomyopathy points to a pathogenic role of Wnt signalling and miRNA dysregulation. Cardiovascular Research, 2019, 115, 739-751.	1.8	40
81	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1805-1819.	1.8	39
82	Cloning and Cellular Distribution of a Group II Phospholipase A2Expressed in the Heart. Journal of Molecular and Cellular Cardiology, 1997, 29, 2095-2106.	0.9	36
83	A novel miR-371a-5p-mediated pathway, leading to BAG3 upregulation in cardiomyocytes in response to epinephrine, is lost in Takotsubo cardiomyopathy. Cell Death and Disease, 2015, 6, e1948-e1948.	2.7	35
84	Deoxycorticosterone Acetate-Salt Mice Exhibit Blood Pressureâ€“Independent Sexual Dimorphism. Hypertension, 2008, 51, 1177-1183.	1.3	34
85	Apoptosis-Inducing Factor Regulates Skeletal Muscle Progenitor Cell Number and Muscle Phenotype. PLoS ONE, 2011, 6, e27283.	1.1	30
86	Ischemic-reperfused isolated working mouse hearts: membrane damage and type IIA phospholipase A2. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H2572-H2580.	1.5	29
87	MicroRNA Regulation in Cardiovascular Disease. Current Drug Targets, 2010, 11, 900-906.	1.0	29
88	Targeting microRNAs in heart failure. Trends in Cardiovascular Medicine, 2016, 26, 99-110.	2.3	29
89	Genetics meets epigenetics: Genetic variants that modulate noncoding RNA in cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 2015, 89, 27-34.	0.9	28
90	Polymorphisms of the antiapoptotic protein bag3 may play a role in the pathogenesis of tako-tsubo cardiomyopathy. International Journal of Cardiology, 2013, 168, 1663-1665.	0.8	27

#	ARTICLE	IF	CITATIONS
91	Extracellular Vesicle miRNAs in the Promotion of Cardiac Neovascularisation. Frontiers in Physiology, 2020, 11, 579892.	1.3	27
92	Peroxisome Proliferator-activated Receptor (PPAR) Gene Profiling Uncovers Insulin-like Growth Factor-1 as a PPARÎ± Target Gene in Cardioprotection. Journal of Biological Chemistry, 2011, 286, 14598-14607.	1.6	25
93	Low-Dose FK506 Blocks Collar-Induced Atherosclerotic Plaque Development and Stabilizes Plaques in ApoE-/- Mice. American Journal of Transplantation, 2005, 5, 1204-1215.	2.6	24
94	miR-199b-5p is a regulator of left ventricular remodeling following myocardial infarction. Non-coding RNA Research, 2017, 2, 18-26.	2.4	24
95	An improved isolated, left ventricular ejecting, murine heart model. Pflugers Archiv European Journal of Physiology, 1999, 437, 182-190.	1.3	23
96	A Calcineurin-NFATc3-Dependent Pathway Regulates Skeletal Muscle Differentiation and Slow Myosin Heavy-Chain Expression. Molecular and Cellular Biology, 2000, 20, 6600-6611.	1.1	22
97	An unbiased silencing screen in muscle cells identifies miR-320a, miR-150, miR-196b, and miR-34c as regulators of skeletal muscle mitochondrial metabolism. Molecular Metabolism, 2017, 6, 1429-1442.	3.0	21
98	Comparison of different chemically modified inhibitors of miR-199b in vivo. Biochemical Pharmacology, 2019, 159, 106-115.	2.0	21
99	Title is missing!. Molecular and Cellular Biochemistry, 1998, 180, 65-73.	1.4	20
100	Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?. Molecular Therapy, 2015, 23, 1810-1818.	3.7	20
101	MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload. European Journal of Heart Failure, 2010, 12, 4-12.	2.9	19
102	Aquaporin 7: the glycerol aquaeductus in the heart. Cardiovascular Research, 2009, 83, 3-4.	1.8	18
103	RNA therapeutics for heart disease. Biochemical Pharmacology, 2018, 155, 468-478.	2.0	18
104	MiR-337-3p Promotes Adipocyte Browning by Inhibiting TWIST1. Cells, 2020, 9, 1056.	1.8	17
105	In calcineurin-induced cardiac hypertrophy expression of Nav1.5, Cx40 and Cx43 is reduced by different mechanisms. Journal of Molecular and Cellular Cardiology, 2008, 45, 373-384.	0.9	16
106	miR-21: a miRaculous Socratic paradox. Cardiovascular Research, 2010, 87, 397-400.	1.8	16
107	Lack of UCP3 does not affect skeletal muscle mitochondrial function under lipid-challenged conditions, but leads to sudden cardiac death. Basic Research in Cardiology, 2014, 109, 447.	2.5	16
108	Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog. Heart Rhythm, 2012, 9, 1875-1883.e2.	0.3	14

#	ARTICLE	IF	CITATIONS
109	Genomic instability in the naturally and prematurely aged myocardium. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
110	Perspectives on Bulk-Tissue RNA Sequencing and Single-Cell RNA Sequencing for Cardiac Transcriptomics. Frontiers in Molecular Medicine, 2022, 2, .	0.6	14
111	A microRNA program regulates the balance between cardiomyocyte hyperplasia and hypertrophy and stimulates cardiac regeneration. Nature Communications, 2021, 12, 4808.	5.8	13
112	Targeting MicroRNA Targets. Circulation Research, 2012, 111, 506-508.	2.0	12
113	Intercellular transfer of miR-200c-3p impairs the angiogenic capacity of cardiac endothelial cells. Molecular Therapy, 2022, 30, 2257-2273.	3.7	12
114	<scp>ESC</scp> Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. European Journal of Heart Failure, 2014, 16, 509-518.	2.9	11
115	MEK1 Inhibits Cardiac PPARÎ± Activity by Direct Interaction and Prevents Its Nuclear Localization. PLoS ONE, 2012, 7, e36799.	1.1	11
116	Calcium cycling in heart failure: how the fast became too furious. Cardiovascular Research, 2004, 62, 439-441.	1.8	10
117	Supplementing Exposure to Hypoxia with a Copper Depleted Diet Does Not Exacerbate Right Ventricular Remodeling in Mice. PLoS ONE, 2014, 9, e92983.	1.1	10
118	miR-223: sailing to terra incognita for microRNAs in platelets. Thrombosis and Haemostasis, 2013, 110, 1112-1113.	1.8	7
119	Circulating miR-216a as a biomarker of metabolic alterations and obesity in women. Non-coding RNA Research, 2020, 5, 144-152.	2.4	7
120	The MEF2 transcriptional target DMPK induces loss of sarcomere structure and cardiomyopathy. Cardiovascular Research, 2018, 114, 1474-1486.	1.8	6
121	Exosomes: scytales in the damaged heart. Annals of Translational Medicine, 2016, 4, 222-222.	0.7	6
122	State-of-the-art on non-coding RNA bioinformatics, diagnostics and therapeutics in cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 2015, 89, 1-2.	0.9	5
123	Non-coding RNAs in cardiac inflammation: key drivers in the pathophysiology of heart failure. Cardiovascular Research, 2022, 118, 2058-2073.	1.8	5
124	Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy. Cells, 2021, 10, 2578.	1.8	5
125	Why publish in the <i>American Journal of Physiology-Heart and Circulatory Physiology</i>?. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H221-H223.	1.5	4
126	Non-coding RNA function in stem cells and Regenerative Medicine. Non-coding RNA Research, 2018, 3, 39-41.	2.4	4

#	ARTICLE	IF	CITATIONS
127	Quaero muneris: Exploring microRNA function in cardiovascular disease. Journal of Molecular and Cellular Cardiology, 2012, 52, 1-2.	0.9	3
128	The adult heart requires baseline expression of the transcription factor Hand2 to withstand right ventricular pressure overload. Cardiovascular Research, 2022, 118, 2688-2702.	1.8	3
129	Human heart failure: our current STATus of knowledge. Cardiovascular Research, 2003, 57, 294-297.	1.8	2
130	Heart spotting. Basic Research in Cardiology, 2008, 103, 228-231.	2.5	2
131	Abstract 896: Cardiomyocyte-derived Mir-200c-3p In Exosomes Affects Endothelial Angiogenic Capacity And Impairs Cardiac Function. Circulation Research, 2019, 125, .	2.0	2
132	TOLL-erating cardiac hypertrophy following pressure overload. Cardiovascular Research, 2005, 68, 178-179.	1.8	1
133	Nix : The Cardiac Styx Between Life and Death. Circulation, 2008, 117, 338-340.	1.6	1
134	Letter concerning: 'Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo'. Cardiovascular Research, 2011, 91, 742-743.	1.8	1
135	Nuclear Calcium Transients. Circulation, 2014, 130, 221-223.	1.6	1
136	Longing for Naiades in Heart Failure âˆ—. Journal of the American College of Cardiology, 2015, 66, 2016-2018.	1.2	1
137	Dichotomy between the transcriptomic landscape of naturally versus accelerated aged murine hearts. Scientific Reports, 2020, 10, 8136.	1.6	1
138	Evolutionarily conserved transcriptional landscape of the heart defining the chamber specific physiology. Genomics, 2021, 113, 3782-3792.	1.3	1
139	Characterization of protein kinase C (PKC) function in cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology, 2001, 33, A16.	0.9	0
140	Unraveling the significance of the hypertrophic calcineurin-NFAT pathway by viral mediated inhibition of its components. Journal of Molecular and Cellular Cardiology, 2001, 33, A102.	0.9	0
141	Linking Cardiac Mechanosensing at the Sarcomere M-Band, Nuclear Factor Î°B Signaling, and Cardiac Remodeling. Hypertension, 2007, 49, 1225-1227.	1.3	0
142	Discrepancy Between Acute and Long-Term Effects of the Calmodulin-Camkii-Calcineurin Pathway on Arrhythmogenesis in the CAVB Dog. Heart Rhythm, 2009, 6, 1693-1694.	0.3	0
143	Towards modern genetics, diagnostics and therapeutics of heart failure in a new era. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2401-2402.	1.8	0
144	If you like it, put a ring on it!. Cardiovascular Research, 2018, 114, 1575-1577.	1.8	0

#	ARTICLE	IF	CITATIONS
145	Epigenetics in cardiac development and human induced pluripotent stem cells. , 2021, , 235-258.		0
146	Apoptosis in Cardiovascular Pathogenesis. , 2009, , 505-521.		0
147	Potential Role of Phospholipase A2 in the Normoxic, Ischemic, and Reperfused Heart. , 1998, , 89-114.		0
148	Long Non-Coding RNAs in Cardiac Hypertrophy. Frontiers in Molecular Medicine, 2022, 2, .	0.6	0